NZ591316A - New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's disease - Google Patents
New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's diseaseInfo
- Publication number
- NZ591316A NZ591316A NZ591316A NZ59131606A NZ591316A NZ 591316 A NZ591316 A NZ 591316A NZ 591316 A NZ591316 A NZ 591316A NZ 59131606 A NZ59131606 A NZ 59131606A NZ 591316 A NZ591316 A NZ 591316A
- Authority
- NZ
- New Zealand
- Prior art keywords
- mmol
- imidazol
- methyl
- pyrimidin
- fluoro
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract description 18
- 208000024827 Alzheimer disease Diseases 0.000 title abstract description 11
- 150000003230 pyrimidines Chemical class 0.000 title abstract description 6
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 title description 9
- 238000004519 manufacturing process Methods 0.000 title description 9
- 238000002560 therapeutic procedure Methods 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 398
- 238000006243 chemical reaction Methods 0.000 claims description 32
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 238000002821 scintillation proximity assay Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 4
- IDSXLJLXYMLSJM-UHFFFAOYSA-N morpholine;propane-1-sulfonic acid Chemical compound C1COCCN1.CCCS(O)(=O)=O IDSXLJLXYMLSJM-UHFFFAOYSA-N 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 3
- 102000001267 GSK3 Human genes 0.000 claims 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 claims 1
- 108060006662 GSK3 Proteins 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 229920004890 Triton X-100 Polymers 0.000 claims 1
- 239000013504 Triton X-100 Substances 0.000 claims 1
- CTCBPRXHVPZNHB-VQFZJOCSSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate;(2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O CTCBPRXHVPZNHB-VQFZJOCSSA-N 0.000 claims 1
- 239000012131 assay buffer Substances 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 238000012417 linear regression Methods 0.000 claims 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 claims 1
- 239000012089 stop solution Substances 0.000 claims 1
- -1 pyrimidine derivative compound Chemical class 0.000 abstract description 102
- 238000000034 method Methods 0.000 abstract description 62
- UQCMOBQFQMVHTA-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1COCCC1N1C(C)=NC=C1C1=NC(N)=NC=C1F UQCMOBQFQMVHTA-UHFFFAOYSA-N 0.000 abstract description 29
- 230000008569 process Effects 0.000 abstract description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 219
- 238000007429 general method Methods 0.000 description 173
- 238000005481 NMR spectroscopy Methods 0.000 description 169
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 116
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 110
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 106
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 90
- 125000000623 heterocyclic group Chemical group 0.000 description 90
- 239000001257 hydrogen Substances 0.000 description 79
- 229910052739 hydrogen Inorganic materials 0.000 description 79
- 239000002585 base Substances 0.000 description 78
- 238000003818 flash chromatography Methods 0.000 description 74
- 239000007787 solid Substances 0.000 description 74
- 229910000024 caesium carbonate Inorganic materials 0.000 description 71
- 239000000203 mixture Substances 0.000 description 68
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 68
- 125000005843 halogen group Chemical group 0.000 description 65
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 64
- 239000000047 product Substances 0.000 description 55
- 150000003839 salts Chemical class 0.000 description 47
- IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 45
- 125000004093 cyano group Chemical group *C#N 0.000 description 45
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 41
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 41
- 125000001072 heteroaryl group Chemical group 0.000 description 40
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 39
- 239000011541 reaction mixture Substances 0.000 description 37
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- 125000003118 aryl group Chemical group 0.000 description 34
- 239000002904 solvent Substances 0.000 description 31
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 30
- 238000000746 purification Methods 0.000 description 30
- 125000004429 atom Chemical group 0.000 description 29
- 239000000243 solution Substances 0.000 description 29
- 239000012453 solvate Substances 0.000 description 29
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 28
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 26
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 22
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 22
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 21
- 239000012074 organic phase Substances 0.000 description 21
- 239000012043 crude product Substances 0.000 description 19
- 125000005842 heteroatom Chemical group 0.000 description 19
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 19
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 18
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- 238000002953 preparative HPLC Methods 0.000 description 18
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 17
- 229910052760 oxygen Inorganic materials 0.000 description 17
- 229910052717 sulfur Inorganic materials 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 101150041968 CDC13 gene Proteins 0.000 description 16
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 16
- 238000010626 work up procedure Methods 0.000 description 16
- 125000003865 brosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)S(*)(=O)=O 0.000 description 15
- 239000012458 free base Substances 0.000 description 15
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 14
- URAFFHFGIKHGML-UHFFFAOYSA-N 4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1COCCC1N1C(C)=NC=C1C1=CC=NC(N)=N1 URAFFHFGIKHGML-UHFFFAOYSA-N 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Substances [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 13
- 206010012289 Dementia Diseases 0.000 description 13
- 229910052786 argon Inorganic materials 0.000 description 13
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 12
- STIAPHVBRDNOAJ-UHFFFAOYSA-N carbamimidoylazanium;carbonate Chemical compound NC(N)=N.NC(N)=N.OC(O)=O STIAPHVBRDNOAJ-UHFFFAOYSA-N 0.000 description 12
- 125000006239 protecting group Chemical group 0.000 description 12
- YDVHAJGGRNBAER-UHFFFAOYSA-N pyrimidin-2-amine;hydrochloride Chemical compound Cl.NC1=NC=CC=N1 YDVHAJGGRNBAER-UHFFFAOYSA-N 0.000 description 12
- KMMHZIBWCXYAAH-UHFFFAOYSA-N 4-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(Br)C=C1 KMMHZIBWCXYAAH-UHFFFAOYSA-N 0.000 description 11
- MPVDXIMFBOLMNW-UHFFFAOYSA-N chembl1615565 Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1N=NC1=CC=CC=C1 MPVDXIMFBOLMNW-UHFFFAOYSA-N 0.000 description 11
- 239000007789 gas Substances 0.000 description 11
- 239000000543 intermediate Substances 0.000 description 11
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 11
- 239000012363 selectfluor Substances 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 9
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000012298 atmosphere Substances 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 239000003643 water by type Substances 0.000 description 9
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 8
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 8
- 239000005909 Kieselgur Substances 0.000 description 8
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 125000002252 acyl group Chemical group 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 8
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 7
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 7
- 201000011240 Frontotemporal dementia Diseases 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- AZQXHLYWUDGOAE-UHFFFAOYSA-N 2-chloro-4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidine Chemical compound CN1C(C)=NC=C1C1=NC(Cl)=NC=C1F AZQXHLYWUDGOAE-UHFFFAOYSA-N 0.000 description 6
- LMFGPGVCUFRLQC-UHFFFAOYSA-N 4-bromo-2-(trifluoromethoxy)benzoic acid Chemical compound OC(=O)C1=CC=C(Br)C=C1OC(F)(F)F LMFGPGVCUFRLQC-UHFFFAOYSA-N 0.000 description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- 208000020925 Bipolar disease Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 229910052744 lithium Inorganic materials 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- LTHSGGMHLKBAIG-UHFFFAOYSA-N methyl 3-[[4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-yl]amino]benzoate Chemical compound COC(=O)C1=CC=CC(NC=2N=C(C(F)=CN=2)C=2N(C(C)=NC=2)C)=C1 LTHSGGMHLKBAIG-UHFFFAOYSA-N 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 125000001963 4 membered heterocyclic group Chemical group 0.000 description 5
- MUGOSUIJVLAPHU-UHFFFAOYSA-N 4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-amine Chemical compound CN1C(C)=NC=C1C1=NC(N)=NC=C1F MUGOSUIJVLAPHU-UHFFFAOYSA-N 0.000 description 5
- KWJZFQQTDGVBOX-UHFFFAOYSA-N 4-[(4-bromophenyl)methyl]morpholine Chemical compound C1=CC(Br)=CC=C1CN1CCOCC1 KWJZFQQTDGVBOX-UHFFFAOYSA-N 0.000 description 5
- QGMHRTDVNDXDBB-UHFFFAOYSA-N 5-methyl-1,2-oxazol-4-amine Chemical compound CC=1ON=CC=1N QGMHRTDVNDXDBB-UHFFFAOYSA-N 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 208000010877 cognitive disease Diseases 0.000 description 5
- 208000017004 dementia pugilistica Diseases 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 201000000980 schizophrenia Diseases 0.000 description 5
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-Bis(diphenylphosphino)propane Substances C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 4
- 238000004293 19F NMR spectroscopy Methods 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 4
- 239000005695 Ammonium acetate Substances 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- 108010001483 Glycogen Synthase Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 4
- 208000037658 Parkinson-dementia complex of Guam Diseases 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- 235000019257 ammonium acetate Nutrition 0.000 description 4
- 229940043376 ammonium acetate Drugs 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 125000003435 aroyl group Chemical group 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- ARRRUEUYMDMPKM-UHFFFAOYSA-M lithium;4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]benzoate Chemical compound [Li+].C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC1=CC=C(C([O-])=O)C=C1 ARRRUEUYMDMPKM-UHFFFAOYSA-M 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- QWWIUYXPVVJVNS-UHFFFAOYSA-N methyl 4-bromo-2-(trifluoromethoxy)benzoate Chemical compound COC(=O)C1=CC=C(Br)C=C1OC(F)(F)F QWWIUYXPVVJVNS-UHFFFAOYSA-N 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 4
- 125000004043 oxo group Chemical group O=* 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- ZDEVMQRPFCQZFA-SECBINFHSA-N (3r)-4-(4-bromophenyl)sulfonyl-3-methylmorpholine Chemical compound C[C@@H]1COCCN1S(=O)(=O)C1=CC=C(Br)C=C1 ZDEVMQRPFCQZFA-SECBINFHSA-N 0.000 description 3
- XUPFFNLTPFNTAZ-UHFFFAOYSA-N (4-amino-2-nitrophenyl)-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(N)C=C1[N+]([O-])=O XUPFFNLTPFNTAZ-UHFFFAOYSA-N 0.000 description 3
- UUDRIQVPMFATFL-UHFFFAOYSA-N (4-amino-3-methylphenyl)-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(N)C(C)=C1 UUDRIQVPMFATFL-UHFFFAOYSA-N 0.000 description 3
- CQIMFAYIBRLNCH-UHFFFAOYSA-N (4-bromophenyl)-pyridin-2-ylmethanone Chemical compound C1=CC(Br)=CC=C1C(=O)C1=CC=CC=N1 CQIMFAYIBRLNCH-UHFFFAOYSA-N 0.000 description 3
- REWSDNIUOJPNDX-BQYQJAHWSA-N (e)-3-(dimethylamino)-1-[2-methyl-3-(1-methylpiperidin-4-yl)imidazol-4-yl]prop-2-en-1-one Chemical compound CN(C)\C=C\C(=O)C1=CN=C(C)N1C1CCN(C)CC1 REWSDNIUOJPNDX-BQYQJAHWSA-N 0.000 description 3
- OGFMGWSIDAUGBV-UHFFFAOYSA-N 1-(4-bromo-2-chlorophenyl)sulfonyl-4-methylpiperazine Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(Br)C=C1Cl OGFMGWSIDAUGBV-UHFFFAOYSA-N 0.000 description 3
- FEMMQDJHUJFDSH-UHFFFAOYSA-N 1-[3-(oxan-4-yl)imidazol-4-yl]ethanone Chemical compound CC(=O)C1=CN=CN1C1CCOCC1 FEMMQDJHUJFDSH-UHFFFAOYSA-N 0.000 description 3
- RYZSYDFTPGMEIT-UHFFFAOYSA-N 1-bromo-4-(2-methoxyethylsulfonyl)benzene Chemical compound COCCS(=O)(=O)C1=CC=C(Br)C=C1 RYZSYDFTPGMEIT-UHFFFAOYSA-N 0.000 description 3
- CDEBGQSVMKSBQZ-UHFFFAOYSA-N 2-(4-bromophenyl)sulfonyl-n,n-diethylethanamine Chemical compound CCN(CC)CCS(=O)(=O)C1=CC=C(Br)C=C1 CDEBGQSVMKSBQZ-UHFFFAOYSA-N 0.000 description 3
- QVILSWLYJYMGRN-UHFFFAOYSA-N 4-bromo-2-(trifluoromethoxy)aniline Chemical compound NC1=CC=C(Br)C=C1OC(F)(F)F QVILSWLYJYMGRN-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 3
- 229910004373 HOAc Inorganic materials 0.000 description 3
- 206010019196 Head injury Diseases 0.000 description 3
- 239000002841 Lewis acid Substances 0.000 description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 3
- YZKKGKRGYQXWKO-UHFFFAOYSA-N [4-amino-3-(trifluoromethoxy)phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(N)C(OC(F)(F)F)=C1 YZKKGKRGYQXWKO-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 238000007080 aromatic substitution reaction Methods 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000013058 crude material Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- BTVSLLUSBYJZSI-UHFFFAOYSA-N ethyl 4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 BTVSLLUSBYJZSI-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 150000007517 lewis acids Chemical class 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 3
- 206010027175 memory impairment Diseases 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 210000001428 peripheral nervous system Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- MCBMXHFLLQLBQH-QPJJXVBHSA-N (e)-3-(dimethylamino)-1-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]prop-2-en-1-one Chemical compound CN(C)\C=C\C(=O)C1=CN=C(C)N1C1CCOCC1 MCBMXHFLLQLBQH-QPJJXVBHSA-N 0.000 description 2
- CGSUMHBDSLBPOV-RAXLEYEMSA-N (z)-1-(3-cyclohexyl-2-methylimidazol-4-yl)-3-(dimethylamino)-2-fluoroprop-2-en-1-one Chemical compound CN(C)\C=C(/F)C(=O)C1=CN=C(C)N1C1CCCCC1 CGSUMHBDSLBPOV-RAXLEYEMSA-N 0.000 description 2
- XADSOKZQQILZEX-XFXZXTDPSA-N (z)-3-(dimethylamino)-2-fluoro-1-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]prop-2-en-1-one Chemical compound CN(C)\C=C(/F)C(=O)C1=CN=C(C)N1C1CCOCC1 XADSOKZQQILZEX-XFXZXTDPSA-N 0.000 description 2
- RKJFNRXOQJIEEE-UHFFFAOYSA-N 1-[3-methyl-2-(trifluoromethyl)imidazol-4-yl]ethanone Chemical compound CC(=O)C1=CN=C(C(F)(F)F)N1C RKJFNRXOQJIEEE-UHFFFAOYSA-N 0.000 description 2
- FJLFSYRGFJDJMQ-UHFFFAOYSA-N 1-bromo-4-methylsulfonylbenzene Chemical compound CS(=O)(=O)C1=CC=C(Br)C=C1 FJLFSYRGFJDJMQ-UHFFFAOYSA-N 0.000 description 2
- UFTGBGFYRWKRLN-UHFFFAOYSA-N 2,2,2-trifluoro-n-methyl-n-(5-methyl-1,2-oxazol-4-yl)acetamide Chemical compound FC(F)(F)C(=O)N(C)C=1C=NOC=1C UFTGBGFYRWKRLN-UHFFFAOYSA-N 0.000 description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- JWJRLABLXQZFAR-UHFFFAOYSA-N 4-(4-bromophenyl)sulfonylmorpholine Chemical compound C1=CC(Br)=CC=C1S(=O)(=O)N1CCOCC1 JWJRLABLXQZFAR-UHFFFAOYSA-N 0.000 description 2
- SJLNPDGNADQQGE-UHFFFAOYSA-N 4-[(4-chloro-2-methylphenyl)methyl]morpholine Chemical compound CC1=CC(Cl)=CC=C1CN1CCOCC1 SJLNPDGNADQQGE-UHFFFAOYSA-N 0.000 description 2
- IGWVTCXEZVURNB-UHFFFAOYSA-N 4-bromo-1-iodo-2-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC(Br)=CC=C1I IGWVTCXEZVURNB-UHFFFAOYSA-N 0.000 description 2
- QOIHZAYTOAGCNP-UHFFFAOYSA-N 4-bromo-2-chloro-1-methylsulfonylbenzene Chemical compound CS(=O)(=O)C1=CC=C(Br)C=C1Cl QOIHZAYTOAGCNP-UHFFFAOYSA-N 0.000 description 2
- OECYEHWJPRPCOH-UHFFFAOYSA-N 4-bromo-2-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC(Br)=CC=C1S(Cl)(=O)=O OECYEHWJPRPCOH-UHFFFAOYSA-N 0.000 description 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- JFZIVITZPGBERZ-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-(4-piperazin-1-ylsulfonylphenyl)pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1S(=O)(=O)N1CCNCC1 JFZIVITZPGBERZ-UHFFFAOYSA-N 0.000 description 2
- XWUFNANHAZTEFC-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[3-methylsulfonyl-4-(morpholin-4-ylmethyl)phenyl]pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1S(C)(=O)=O)=CC=C1CN1CCOCC1 XWUFNANHAZTEFC-UHFFFAOYSA-N 0.000 description 2
- HPWNIPMSABCNAE-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[4-(oxan-2-ylmethylsulfonyl)phenyl]pyrimidin-2-amine Chemical compound C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1S(=O)(=O)CC1CCCCO1 HPWNIPMSABCNAE-UHFFFAOYSA-N 0.000 description 2
- FNHROSXUOGTTFM-UHFFFAOYSA-N 5-fluoro-n-[3-methyl-4-(morpholin-4-ylmethyl)phenyl]-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1C)=CC=C1CN1CCOCC1 FNHROSXUOGTTFM-UHFFFAOYSA-N 0.000 description 2
- QCSSTYNVUYCZAQ-UHFFFAOYSA-N 5-fluoro-n-[4-(morpholin-4-ylmethyl)phenyl]-4-[3-(oxan-4-yl)-2-(trifluoromethyl)imidazol-4-yl]pyrimidin-2-amine;hydrochloride Chemical compound Cl.N1=C(C=2N(C(=NC=2)C(F)(F)F)C2CCOCC2)C(F)=CN=C1NC(C=C1)=CC=C1CN1CCOCC1 QCSSTYNVUYCZAQ-UHFFFAOYSA-N 0.000 description 2
- OQKLTFPVRPDGRN-UHFFFAOYSA-N 6-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-1,1-dioxo-2,3-dihydrothiochromen-4-one;hydrochloride Chemical compound Cl.CC1=NC=C(C=2C(=CN=C(NC=3C=C4C(S(CCC4=O)(=O)=O)=CC=3)N=2)F)N1C1CCOCC1 OQKLTFPVRPDGRN-UHFFFAOYSA-N 0.000 description 2
- LDARYERYIPQHMP-UHFFFAOYSA-N 6-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-1,1-dioxo-3,4-dihydro-2h-thiochromen-4-ol;hydrochloride Chemical compound Cl.CC1=NC=C(C=2C(=CN=C(NC=3C=C4C(S(CCC4O)(=O)=O)=CC=3)N=2)F)N1C1CCOCC1 LDARYERYIPQHMP-UHFFFAOYSA-N 0.000 description 2
- FHCSBLWRGCOVPT-UHFFFAOYSA-N AZD2858 Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(C=2N=C(C(N)=NC=2)C(=O)NC=2C=NC=CC=2)C=C1 FHCSBLWRGCOVPT-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000014060 Niemann-Pick disease Diseases 0.000 description 2
- UQONAEXHTGDOIH-AWEZNQCLSA-N O=C(N1CC[C@@H](C1)N1CCCC1=O)C1=CC2=C(NC3(CC3)CCO2)N=C1 Chemical compound O=C(N1CC[C@@H](C1)N1CCCC1=O)C1=CC2=C(NC3(CC3)CCO2)N=C1 UQONAEXHTGDOIH-AWEZNQCLSA-N 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- SINAKXHPXDZHGA-UHFFFAOYSA-N [3-[[4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-yl]amino]phenyl]-[3-(hydroxymethyl)piperidin-1-yl]methanone Chemical compound CN1C(C)=NC=C1C1=NC(NC=2C=C(C=CC=2)C(=O)N2CC(CO)CCC2)=NC=C1F SINAKXHPXDZHGA-UHFFFAOYSA-N 0.000 description 2
- MXUBUUIXLWLCRF-UHFFFAOYSA-N [4-[[4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-yl]amino]-2-(trifluoromethoxy)phenyl]-(4-methylpiperazin-1-yl)methanone;hydrochloride Chemical compound Cl.C1CN(C)CCN1C(=O)C(C(=C1)OC(F)(F)F)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C)=N1 MXUBUUIXLWLCRF-UHFFFAOYSA-N 0.000 description 2
- DBDXVTYNNKXTKP-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(4-fluoropiperidin-1-yl)methanone;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)N1CCC(F)CC1 DBDXVTYNNKXTKP-UHFFFAOYSA-N 0.000 description 2
- LOBZGPAPPRXNJG-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-pyridin-2-ylmethanone;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)C1=CC=CC=N1 LOBZGPAPPRXNJG-UHFFFAOYSA-N 0.000 description 2
- UOYZAQZJEFUCIP-UHFFFAOYSA-N [4-[[5-fluoro-4-[3-(oxan-4-yl)-2-(trifluoromethyl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone;hydrochloride Chemical compound Cl.C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(=NC=2)C(F)(F)F)C2CCOCC2)=N1 UOYZAQZJEFUCIP-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000005101 aryl methoxy carbonyl group Chemical group 0.000 description 2
- 125000005002 aryl methyl group Chemical group 0.000 description 2
- XCPHTBBUCKHUBS-UHFFFAOYSA-N azetidin-1-yl-[4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]methanone;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)N1CCC1 XCPHTBBUCKHUBS-UHFFFAOYSA-N 0.000 description 2
- ZFMABTDZKJITRY-UHFFFAOYSA-N azetidin-1-yl-[4-bromo-2-(trifluoromethoxy)phenyl]methanone Chemical compound FC(F)(F)OC1=CC(Br)=CC=C1C(=O)N1CCC1 ZFMABTDZKJITRY-UHFFFAOYSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- KWTSZCJMWHGPOS-UHFFFAOYSA-M chloro(trimethyl)stannane Chemical compound C[Sn](C)(C)Cl KWTSZCJMWHGPOS-UHFFFAOYSA-M 0.000 description 2
- 230000006999 cognitive decline Effects 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- WGLKCJSZMNTANV-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-3-[[4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-yl]amino]-n-methylbenzamide;hydrochloride Chemical compound Cl.CN(C)CCCN(C)C(=O)C1=CC=CC(NC=2N=C(C(F)=CN=2)C=2N(C(C)=NC=2)C)=C1 WGLKCJSZMNTANV-UHFFFAOYSA-N 0.000 description 2
- QVNQBICOSFVRIE-UHFFFAOYSA-N n-[4-[1-(azetidin-1-yl)ethyl]phenyl]-5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C=1C=C(NC=2N=C(C(F)=CN=2)C=2N(C(C)=NC=2)C2CCOCC2)C=CC=1C(C)N1CCC1 QVNQBICOSFVRIE-UHFFFAOYSA-N 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- NRTTUJLILQPENP-UHFFFAOYSA-N pyridine-2-carbaldehyde;hydrochloride Chemical compound Cl.O=CC1=CC=CC=N1 NRTTUJLILQPENP-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- AQKVPXFKSGCQHL-UHFFFAOYSA-N tert-butyl 4-(4-bromophenyl)sulfonylpiperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1S(=O)(=O)C1=CC=C(Br)C=C1 AQKVPXFKSGCQHL-UHFFFAOYSA-N 0.000 description 2
- 150000003527 tetrahydropyrans Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- JUHQUEWVIIDBNH-UHFFFAOYSA-N (3,3-difluoroazetidin-1-yl)-[4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]methanone;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)N1CC(F)(F)C1 JUHQUEWVIIDBNH-UHFFFAOYSA-N 0.000 description 1
- UHDXDZQXNNJWDY-UHFFFAOYSA-N (3,3-difluoropyrrolidin-1-yl)-[4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]methanone;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)N1CCC(F)(F)C1 UHDXDZQXNNJWDY-UHFFFAOYSA-N 0.000 description 1
- SFWWGMKXCYLZEG-RXMQYKEDSA-N (3r)-3-methylmorpholine Chemical compound C[C@@H]1COCCN1 SFWWGMKXCYLZEG-RXMQYKEDSA-N 0.000 description 1
- RBKHNGHPZZZJCI-UHFFFAOYSA-N (4-aminophenyl)-phenylmethanone Chemical compound C1=CC(N)=CC=C1C(=O)C1=CC=CC=C1 RBKHNGHPZZZJCI-UHFFFAOYSA-N 0.000 description 1
- AUDGHHREDWBFOE-UHFFFAOYSA-N (4-ethylpiperazin-1-yl)-[4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]methanone;hydrochloride Chemical compound Cl.C1CN(CC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 AUDGHHREDWBFOE-UHFFFAOYSA-N 0.000 description 1
- NDYMQOUYJJXCKJ-UHFFFAOYSA-N (4-fluorophenyl)-morpholin-4-ylmethanone Chemical compound C1=CC(F)=CC=C1C(=O)N1CCOCC1 NDYMQOUYJJXCKJ-UHFFFAOYSA-N 0.000 description 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
- MDRYGXGPMGQHMC-UHFFFAOYSA-N 1,1-dimethoxy-n,n-dimethylmethanamine;n,n-dimethylformamide Chemical compound CN(C)C=O.COC(OC)N(C)C MDRYGXGPMGQHMC-UHFFFAOYSA-N 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- YYKMFIBMFKKXJJ-UHFFFAOYSA-N 1-(4-bromo-2-methylphenyl)sulfonyl-4-methylpiperazine Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(Br)C=C1C YYKMFIBMFKKXJJ-UHFFFAOYSA-N 0.000 description 1
- ULLAFWIGAOOHJV-UHFFFAOYSA-N 1-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]ethanone Chemical compound CC(=O)C1=CN=C(C)N1C1CCOCC1 ULLAFWIGAOOHJV-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
- FXHRAKUEZPSMLJ-UHFFFAOYSA-N 1-methyl-1,4-diazepane Chemical compound CN1CCCNCC1 FXHRAKUEZPSMLJ-UHFFFAOYSA-N 0.000 description 1
- HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 1
- WHKWMTXTYKVFLK-UHFFFAOYSA-N 1-propan-2-ylpiperazine Chemical compound CC(C)N1CCNCC1 WHKWMTXTYKVFLK-UHFFFAOYSA-N 0.000 description 1
- WHPFEQUEHBULBW-UHFFFAOYSA-N 2,4-dichloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1Cl WHPFEQUEHBULBW-UHFFFAOYSA-N 0.000 description 1
- JEYIKZQANLPVBY-UHFFFAOYSA-N 2-(4-bromophenyl)sulfonylethanol Chemical compound OCCS(=O)(=O)C1=CC=C(Br)C=C1 JEYIKZQANLPVBY-UHFFFAOYSA-N 0.000 description 1
- MHNWCBOXPOLLIB-UHFFFAOYSA-N 2-(bromomethyl)oxane Chemical compound BrCC1CCCCO1 MHNWCBOXPOLLIB-UHFFFAOYSA-N 0.000 description 1
- DGRDAMKKVRSHBK-UHFFFAOYSA-N 2-[(4-bromophenyl)sulfonylmethyl]oxane Chemical compound C1=CC(Br)=CC=C1S(=O)(=O)CC1OCCCC1 DGRDAMKKVRSHBK-UHFFFAOYSA-N 0.000 description 1
- DCDIEFUKOHCORY-UHFFFAOYSA-N 2-[4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]sulfonylethanol Chemical compound C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC1=CC=C(S(=O)(=O)CCO)C=C1 DCDIEFUKOHCORY-UHFFFAOYSA-N 0.000 description 1
- LVBDLAPMBZGOMR-UHFFFAOYSA-N 2-aminobenzamide;hydrochloride Chemical compound Cl.NC(=O)C1=CC=CC=C1N LVBDLAPMBZGOMR-UHFFFAOYSA-N 0.000 description 1
- WRYDGMWSKBGVHS-UHFFFAOYSA-N 2-bromo-n,n-diethylethanamine Chemical compound CCN(CC)CCBr WRYDGMWSKBGVHS-UHFFFAOYSA-N 0.000 description 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- CDBAEFXTCRKJPZ-UHFFFAOYSA-N 3,3-difluoroazetidine;hydron;chloride Chemical compound Cl.FC1(F)CNC1 CDBAEFXTCRKJPZ-UHFFFAOYSA-N 0.000 description 1
- UQRLKWGPEVNVHT-UHFFFAOYSA-N 3,5-dichloroaniline Chemical compound NC1=CC(Cl)=CC(Cl)=C1 UQRLKWGPEVNVHT-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- IWTFTXAHVPOGGS-UHFFFAOYSA-N 3-[[4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-yl]amino]-n-(3-methoxypropyl)benzamide;hydrochloride Chemical compound Cl.COCCCNC(=O)C1=CC=CC(NC=2N=C(C(F)=CN=2)C=2N(C(C)=NC=2)C)=C1 IWTFTXAHVPOGGS-UHFFFAOYSA-N 0.000 description 1
- ADLMNARJRRPSOT-UHFFFAOYSA-N 3-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]benzonitrile;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC1=CC=CC(C#N)=C1 ADLMNARJRRPSOT-UHFFFAOYSA-N 0.000 description 1
- PJGOLCXVWIYXRQ-UHFFFAOYSA-N 3-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC(Br)=C1 PJGOLCXVWIYXRQ-UHFFFAOYSA-N 0.000 description 1
- STXAVEHFKAXGOX-UHFFFAOYSA-N 3-bromobenzonitrile Chemical compound BrC1=CC=CC(C#N)=C1 STXAVEHFKAXGOX-UHFFFAOYSA-N 0.000 description 1
- VTFGJEYZCUWSAM-UHFFFAOYSA-N 3-methoxy-5-(trifluoromethyl)aniline Chemical compound COC1=CC(N)=CC(C(F)(F)F)=C1 VTFGJEYZCUWSAM-UHFFFAOYSA-N 0.000 description 1
- FAXDZWQIWUSWJH-UHFFFAOYSA-N 3-methoxypropan-1-amine Chemical compound COCCCN FAXDZWQIWUSWJH-UHFFFAOYSA-N 0.000 description 1
- VTEAOOUKGTUNBL-UHFFFAOYSA-N 4-(2,3-dimethylimidazol-4-yl)-5-fluoro-n-(4-methylsulfonylphenyl)pyrimidin-2-amine Chemical compound CN1C(C)=NC=C1C1=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=NC=C1F VTEAOOUKGTUNBL-UHFFFAOYSA-N 0.000 description 1
- XTWRYVIQIXIGHG-UHFFFAOYSA-N 4-(2,3-dimethylimidazol-4-yl)-5-fluoro-n-[3-methyl-4-(4-methylpiperazin-1-yl)sulfonylphenyl]pyrimidin-2-amine Chemical compound C1CN(C)CCN1S(=O)(=O)C(C(=C1)C)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C)=N1 XTWRYVIQIXIGHG-UHFFFAOYSA-N 0.000 description 1
- CIWYJYVVLCBEJB-UHFFFAOYSA-N 4-(2,3-dimethylimidazol-4-yl)-5-fluoro-n-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1CN(C)CCN1CC(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C)=N1 CIWYJYVVLCBEJB-UHFFFAOYSA-N 0.000 description 1
- SEUVVDWIMKUSAQ-UHFFFAOYSA-N 4-(3-cyclohexyl-2-methylimidazol-4-yl)-5-fluoropyrimidin-2-amine Chemical compound C1CCCCC1N1C(C)=NC=C1C1=NC(N)=NC=C1F SEUVVDWIMKUSAQ-UHFFFAOYSA-N 0.000 description 1
- XNSOYMCXSMYWBW-UHFFFAOYSA-N 4-[(4-bromo-2-methylsulfonylphenyl)methyl]morpholine Chemical compound CS(=O)(=O)C1=CC(Br)=CC=C1CN1CCOCC1 XNSOYMCXSMYWBW-UHFFFAOYSA-N 0.000 description 1
- NCRGTUOKKUWAEU-UHFFFAOYSA-N 4-[1-(4-bromophenyl)ethyl]morpholine Chemical compound C=1C=C(Br)C=CC=1C(C)N1CCOCC1 NCRGTUOKKUWAEU-UHFFFAOYSA-N 0.000 description 1
- NCUTUFSXCVKNAD-UHFFFAOYSA-N 4-[2-(4-bromophenyl)ethyl]morpholine Chemical compound C1=CC(Br)=CC=C1CCN1CCOCC1 NCUTUFSXCVKNAD-UHFFFAOYSA-N 0.000 description 1
- QLNHZJLXRCTCMN-UHFFFAOYSA-N 4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-(4-methylsulfonylphenyl)pyrimidin-2-amine Chemical compound C1COCCC1N1C(C)=NC=C1C(N=1)=CC=NC=1NC1=CC=C(S(C)(=O)=O)C=C1 QLNHZJLXRCTCMN-UHFFFAOYSA-N 0.000 description 1
- HYESJXMPFNNNAW-UHFFFAOYSA-N 4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-(4-morpholin-4-ylsulfonylphenyl)pyrimidin-2-amine Chemical compound C1COCCC1N1C(C)=NC=C1C(N=1)=CC=NC=1NC(C=C1)=CC=C1S(=O)(=O)N1CCOCC1 HYESJXMPFNNNAW-UHFFFAOYSA-N 0.000 description 1
- KJJXNFGGNQIJRQ-UHFFFAOYSA-N 4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[3-(4-methylpiperazin-1-yl)sulfonylphenyl]pyrimidin-2-amine Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=CC(NC=2N=C(C=CN=2)C=2N(C(C)=NC=2)C2CCOCC2)=C1 KJJXNFGGNQIJRQ-UHFFFAOYSA-N 0.000 description 1
- WDBIOFPEYDNNET-UHFFFAOYSA-N 4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]pyrimidin-2-amine Chemical compound C1CN(C)CCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC=CC(C=2N(C(C)=NC=2)C2CCOCC2)=N1 WDBIOFPEYDNNET-UHFFFAOYSA-N 0.000 description 1
- BWNKOIBHTVEFEQ-UHFFFAOYSA-N 4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[4-(4-propan-2-ylpiperazin-1-yl)sulfonylphenyl]pyrimidin-2-amine Chemical compound C1CN(C(C)C)CCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC=CC(C=2N(C(C)=NC=2)C2CCOCC2)=N1 BWNKOIBHTVEFEQ-UHFFFAOYSA-N 0.000 description 1
- HDLRWDBVGGDOBV-UHFFFAOYSA-N 4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[4-(morpholin-4-ylmethyl)phenyl]pyrimidin-2-amine Chemical compound C1COCCC1N1C(C)=NC=C1C(N=1)=CC=NC=1NC(C=C1)=CC=C1CN1CCOCC1 HDLRWDBVGGDOBV-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- OSYLOIKABTTWMD-UHFFFAOYSA-N 4-[[4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-n-(1-methylpiperidin-4-yl)benzenesulfonamide Chemical compound C1CN(C)CCC1NS(=O)(=O)C(C=C1)=CC=C1NC1=NC=CC(C=2N(C(C)=NC=2)C2CCOCC2)=N1 OSYLOIKABTTWMD-UHFFFAOYSA-N 0.000 description 1
- CIUVREIHECGYBX-UHFFFAOYSA-N 4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-n,n-dimethylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N(C)C)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 CIUVREIHECGYBX-UHFFFAOYSA-N 0.000 description 1
- DJNDNOZJRVMSRE-UHFFFAOYSA-N 4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-n-(2-hydroxyethyl)benzamide;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC1=CC=C(C(=O)NCCO)C=C1 DJNDNOZJRVMSRE-UHFFFAOYSA-N 0.000 description 1
- LXZBSHXSXUNDAQ-UHFFFAOYSA-N 4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-n-(2-morpholin-4-ylethyl)benzamide;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)NCCN1CCOCC1 LXZBSHXSXUNDAQ-UHFFFAOYSA-N 0.000 description 1
- JHHGIBQYWIETCQ-UHFFFAOYSA-N 4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-n-(2-piperidin-1-ylethyl)benzamide;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)NCCN1CCCCC1 JHHGIBQYWIETCQ-UHFFFAOYSA-N 0.000 description 1
- JOVUROKJGTYMBQ-UHFFFAOYSA-N 4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-n-(3-methoxypropyl)benzamide;hydrochloride Chemical compound Cl.C1=CC(C(=O)NCCCOC)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 JOVUROKJGTYMBQ-UHFFFAOYSA-N 0.000 description 1
- JNYHDACLEJTONY-UHFFFAOYSA-N 4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-n-(oxan-4-yl)benzamide;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)NC1CCOCC1 JNYHDACLEJTONY-UHFFFAOYSA-N 0.000 description 1
- NBPRKEBCDFFNIL-UHFFFAOYSA-N 4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-n-(oxolan-3-yl)benzamide;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)NC1CCOC1 NBPRKEBCDFFNIL-UHFFFAOYSA-N 0.000 description 1
- JWCZGMGARIPEHY-UHFFFAOYSA-N 4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-n-methylbenzamide;hydrochloride Chemical compound Cl.C1=CC(C(=O)NC)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 JWCZGMGARIPEHY-UHFFFAOYSA-N 0.000 description 1
- QBCRHIGMWJTDCA-UHFFFAOYSA-N 4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-n-propan-2-ylbenzamide;hydrochloride Chemical compound Cl.C1=CC(C(=O)NC(C)C)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 QBCRHIGMWJTDCA-UHFFFAOYSA-N 0.000 description 1
- BDXZIUJTKUIELX-UHFFFAOYSA-N 4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]benzonitrile;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC1=CC=C(C#N)C=C1 BDXZIUJTKUIELX-UHFFFAOYSA-N 0.000 description 1
- SAJYSJVBNGUWJK-UHFFFAOYSA-N 4-amino-2-nitrobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C([N+]([O-])=O)=C1 SAJYSJVBNGUWJK-UHFFFAOYSA-N 0.000 description 1
- IXJFWBNYFTWBOR-UHFFFAOYSA-N 4-amino-3-(trifluoromethoxy)benzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1OC(F)(F)F IXJFWBNYFTWBOR-UHFFFAOYSA-N 0.000 description 1
- NHFKECPTBZZFBC-UHFFFAOYSA-N 4-amino-3-methylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1N NHFKECPTBZZFBC-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- DJWJDMOGILQESS-UHFFFAOYSA-N 4-bromo-1-methylsulfonyl-2-(trifluoromethyl)benzene Chemical compound CS(=O)(=O)C1=CC=C(Br)C=C1C(F)(F)F DJWJDMOGILQESS-UHFFFAOYSA-N 0.000 description 1
- JAVZWSOFJKYSDY-UHFFFAOYSA-N 4-bromo-2-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C=C1Cl JAVZWSOFJKYSDY-UHFFFAOYSA-N 0.000 description 1
- KNBSFUSBZNMAKU-UHFFFAOYSA-N 4-bromo-2-methylbenzenesulfonyl chloride Chemical compound CC1=CC(Br)=CC=C1S(Cl)(=O)=O KNBSFUSBZNMAKU-UHFFFAOYSA-N 0.000 description 1
- RVCJOGNLYVNRDN-UHFFFAOYSA-N 4-bromo-2-methylbenzoic acid Chemical compound CC1=CC(Br)=CC=C1C(O)=O RVCJOGNLYVNRDN-UHFFFAOYSA-N 0.000 description 1
- KMXMXSSAUZKLCE-UHFFFAOYSA-N 4-bromo-2-methylsulfonylbenzaldehyde Chemical compound CS(=O)(=O)C1=CC(Br)=CC=C1C=O KMXMXSSAUZKLCE-UHFFFAOYSA-N 0.000 description 1
- LSUJRBJIQNLQKL-UHFFFAOYSA-N 4-bromo-2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC(Br)=CC=C1C(O)=O LSUJRBJIQNLQKL-UHFFFAOYSA-N 0.000 description 1
- NRGTZJXYAAGKQJ-UHFFFAOYSA-N 4-bromo-n,n-diethylbenzenesulfonamide Chemical compound CCN(CC)S(=O)(=O)C1=CC=C(Br)C=C1 NRGTZJXYAAGKQJ-UHFFFAOYSA-N 0.000 description 1
- XIBVAWGPYWOSHA-UHFFFAOYSA-N 4-bromo-n-(1-methylpiperidin-4-yl)benzenesulfonamide Chemical compound C1CN(C)CCC1NS(=O)(=O)C1=CC=C(Br)C=C1 XIBVAWGPYWOSHA-UHFFFAOYSA-N 0.000 description 1
- DENKGPBHLYFNGK-UHFFFAOYSA-N 4-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Br)C=C1 DENKGPBHLYFNGK-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- UFEYMXHWIHFRBX-UHFFFAOYSA-N 4-chloro-2-methoxybenzoic acid Chemical compound COC1=CC(Cl)=CC=C1C(O)=O UFEYMXHWIHFRBX-UHFFFAOYSA-N 0.000 description 1
- YLXSEAVHGJWSTK-UHFFFAOYSA-N 4-chloro-2-methylbenzaldehyde Chemical compound CC1=CC(Cl)=CC=C1C=O YLXSEAVHGJWSTK-UHFFFAOYSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
- GJNGXPDXRVXSEH-UHFFFAOYSA-N 4-chlorobenzonitrile Chemical compound ClC1=CC=C(C#N)C=C1 GJNGXPDXRVXSEH-UHFFFAOYSA-N 0.000 description 1
- IXENWFQXVCOHAZ-UHFFFAOYSA-N 4-fluoropiperidine;hydrochloride Chemical compound Cl.FC1CCNCC1 IXENWFQXVCOHAZ-UHFFFAOYSA-N 0.000 description 1
- BLFWGFFZXXRNOQ-UHFFFAOYSA-N 5-[5-fluoro-2-[4-(4-methylpiperazin-1-yl)sulfonylanilino]pyrimidin-4-yl]-1-(oxan-4-yl)imidazole-2-carbonitrile Chemical compound C1CN(C)CCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C#N)=NC=2)C2CCOCC2)=N1 BLFWGFFZXXRNOQ-UHFFFAOYSA-N 0.000 description 1
- VPXNDAHXDVIAAQ-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(1-methylpiperidin-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1CN(C)CCC1N1C(C=2C(=CN=C(N)N=2)F)=CN=C1C VPXNDAHXDVIAAQ-UHFFFAOYSA-N 0.000 description 1
- JHVNKPANIZNDOB-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-(4-methylsulfonylphenyl)pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC1=CC=C(S(C)(=O)=O)C=C1 JHVNKPANIZNDOB-UHFFFAOYSA-N 0.000 description 1
- KVUCXDUGBPIVIY-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-(4-propan-2-ylsulfonylphenyl)pyrimidin-2-amine Chemical compound C1=CC(S(=O)(=O)C(C)C)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 KVUCXDUGBPIVIY-UHFFFAOYSA-N 0.000 description 1
- CUXVJGARBZCZCY-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-(4-pyrrolidin-1-ylsulfonylphenyl)pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1S(=O)(=O)N1CCCC1 CUXVJGARBZCZCY-UHFFFAOYSA-N 0.000 description 1
- BMCLFHVOOIZFNK-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[4-(1-morpholin-4-ylethyl)phenyl]pyrimidin-2-amine Chemical compound C=1C=C(NC=2N=C(C(F)=CN=2)C=2N(C(C)=NC=2)C2CCOCC2)C=CC=1C(C)N1CCOCC1 BMCLFHVOOIZFNK-UHFFFAOYSA-N 0.000 description 1
- UTFUIZWRDLATQF-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[4-(2-morpholin-4-ylethyl)phenyl]pyrimidin-2-amine Chemical compound C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1CCN1CCOCC1 UTFUIZWRDLATQF-UHFFFAOYSA-N 0.000 description 1
- OTGRAAUTGFNVIC-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1CN(C)CCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 OTGRAAUTGFNVIC-UHFFFAOYSA-N 0.000 description 1
- ZCNYDSWSOIKGPQ-UHFFFAOYSA-N 5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]-n-[4-methylsulfonyl-3-(trifluoromethyl)phenyl]pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC1=CC=C(S(C)(=O)=O)C(C(F)(F)F)=C1 ZCNYDSWSOIKGPQ-UHFFFAOYSA-N 0.000 description 1
- IOLWECNTCVXLQV-UHFFFAOYSA-N 5-fluoro-4-[3-methyl-2-(trifluoromethyl)imidazol-4-yl]-n-[4-(morpholin-4-ylmethyl)phenyl]pyrimidin-2-amine;hydrochloride Chemical compound Cl.N1=C(C(F)(F)F)N(C)C(C=2C(=CN=C(NC=3C=CC(CN4CCOCC4)=CC=3)N=2)F)=C1 IOLWECNTCVXLQV-UHFFFAOYSA-N 0.000 description 1
- MVSNVAGWRVEZEP-UHFFFAOYSA-N 5-fluoro-n-[3-methyl-4-(4-methylpiperazin-1-yl)sulfonylphenyl]-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1CN(C)CCN1S(=O)(=O)C(C(=C1)C)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 MVSNVAGWRVEZEP-UHFFFAOYSA-N 0.000 description 1
- KWPKLLKLLVEXEJ-UHFFFAOYSA-N 5-fluoro-n-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-4-[3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1CN(C)CCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C=NC=2)C2CCOCC2)=N1 KWPKLLKLLVEXEJ-UHFFFAOYSA-N 0.000 description 1
- DLHJFTBEXSBEFV-UHFFFAOYSA-N 5-fluoro-n-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-4-[3-methyl-2-(trifluoromethyl)imidazol-4-yl]pyrimidin-2-amine;hydrochloride Chemical compound Cl.C1CN(C)CCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(=NC=2)C(F)(F)F)C)=N1 DLHJFTBEXSBEFV-UHFFFAOYSA-N 0.000 description 1
- NVAHGLXBXBUJLJ-MRXNPFEDSA-N 5-fluoro-n-[4-[(3r)-3-methylmorpholin-4-yl]sulfonylphenyl]-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C[C@@H]1COCCN1S(=O)(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 NVAHGLXBXBUJLJ-MRXNPFEDSA-N 0.000 description 1
- ITIVWLXGVTYUJH-PMACEKPBSA-N 5-fluoro-n-[4-[[(1s,4s)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]sulfonyl]phenyl]-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C([C@]1(N(C[C@]2([H])C1)C)[H])N2S(=O)(=O)C(C=C1)=CC=C1NC(N=1)=NC=C(F)C=1C1=CN=C(C)N1C1CCOCC1 ITIVWLXGVTYUJH-PMACEKPBSA-N 0.000 description 1
- ZFZPMYLZPMMUQA-UHFFFAOYSA-N 6-chloro-1,1-dioxo-2,3-dihydrothiochromen-4-one Chemical compound O=C1CCS(=O)(=O)C=2C1=CC(Cl)=CC=2 ZFZPMYLZPMMUQA-UHFFFAOYSA-N 0.000 description 1
- OLYHNACXERPNAM-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-thiochromen-4-ol Chemical compound C1=C(Cl)C=C2C(O)CCS(=O)(=O)C2=C1 OLYHNACXERPNAM-UHFFFAOYSA-N 0.000 description 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 101100515517 Arabidopsis thaliana XI-I gene Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- MWHHJYUHCZWSLS-UHFFFAOYSA-N FC=1C=C(C=CC1C1=C2CNC(C2=C(C=C1)C=1NC(=CN1)C)=O)NC(=O)NC1=C(C=C(C=C1F)F)F Chemical compound FC=1C=C(C=CC1C1=C2CNC(C2=C(C=C1)C=1NC(=CN1)C)=O)NC(=O)NC1=C(C=C(C=C1F)F)F MWHHJYUHCZWSLS-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-IGMARMGPSA-N Fluorine-19 Chemical compound [19F] YCKRFDGAMUMZLT-IGMARMGPSA-N 0.000 description 1
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- VJRZCJVVNSDXRO-UHFFFAOYSA-N [2-chloro-4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C(=C1)Cl)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 VJRZCJVVNSDXRO-UHFFFAOYSA-N 0.000 description 1
- ZSSPELLDAXMBJI-UHFFFAOYSA-N [4-[[4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-yl]amino]-2-nitrophenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C(=C1)[N+]([O-])=O)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C)=N1 ZSSPELLDAXMBJI-UHFFFAOYSA-N 0.000 description 1
- SLIVRYSHXOJBQQ-UHFFFAOYSA-N [4-[[4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-yl]amino]phenyl]-piperidin-1-ylmethanone;hydrochloride Chemical compound Cl.CN1C(C)=NC=C1C1=NC(NC=2C=CC(=CC=2)C(=O)N2CCCCC2)=NC=C1F SLIVRYSHXOJBQQ-UHFFFAOYSA-N 0.000 description 1
- ZTOCZGLOPBKZCP-UHFFFAOYSA-N [4-[[4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-yl]amino]phenyl]-pyridin-2-ylmethanol Chemical compound CN1C(C)=NC=C1C1=NC(NC=2C=CC(=CC=2)C(O)C=2N=CC=CC=2)=NC=C1F ZTOCZGLOPBKZCP-UHFFFAOYSA-N 0.000 description 1
- OVRDGLABTIKZBZ-UHFFFAOYSA-N [4-[[4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-yl]amino]phenyl]-pyridin-2-ylmethanone;hydrochloride Chemical compound Cl.CN1C(C)=NC=C1C1=NC(NC=2C=CC(=CC=2)C(=O)C=2N=CC=CC=2)=NC=C1F OVRDGLABTIKZBZ-UHFFFAOYSA-N 0.000 description 1
- GQFRPCCALAGDPN-UHFFFAOYSA-N [4-[[4-(2,3-dimethylimidazol-4-yl)pyrimidin-2-yl]amino]phenyl]-pyridin-2-ylmethanone Chemical compound CN1C(C)=NC=C1C1=CC=NC(NC=2C=CC(=CC=2)C(=O)C=2N=CC=CC=2)=N1 GQFRPCCALAGDPN-UHFFFAOYSA-N 0.000 description 1
- ZDHGAOPRJUEXDP-UHFFFAOYSA-N [4-[[4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=CC(C=2N(C(C)=NC=2)C2CCOCC2)=N1 ZDHGAOPRJUEXDP-UHFFFAOYSA-N 0.000 description 1
- BUQKKNYYABDKOK-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-2-methoxyphenyl]-(4-methylpiperazin-1-yl)methanone;hydrochloride Chemical compound Cl.C=1C=C(C(=O)N2CCN(C)CC2)C(OC)=CC=1NC(N=1)=NC=C(F)C=1C1=CN=C(C)N1C1CCOCC1 BUQKKNYYABDKOK-UHFFFAOYSA-N 0.000 description 1
- NPMJRGJVURWZIN-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]-2-methylsulfonylphenyl]-(4-methylpiperazin-1-yl)methanone;hydrochloride Chemical compound Cl.C1CN(C)CCN1C(=O)C(C(=C1)S(C)(=O)=O)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 NPMJRGJVURWZIN-UHFFFAOYSA-N 0.000 description 1
- TZOGWQIUAPPXRK-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(1,4-oxazepan-4-yl)methanone;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)N1CCCOCC1 TZOGWQIUAPPXRK-UHFFFAOYSA-N 0.000 description 1
- WEPABZWWVXDISQ-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(3-fluoropyrrolidin-1-yl)methanone;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)N1CCC(F)C1 WEPABZWWVXDISQ-UHFFFAOYSA-N 0.000 description 1
- RSYKUWQLLZMBSK-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(3-hydroxypyrrolidin-1-yl)methanone;hydrochloride Chemical compound Cl.C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1C(=O)N1CCC(O)C1 RSYKUWQLLZMBSK-UHFFFAOYSA-N 0.000 description 1
- MLNSPQGDZLGFAY-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(4-methyl-1,4-diazepan-1-yl)methanone;hydrochloride Chemical compound Cl.C1CN(C)CCCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 MLNSPQGDZLGFAY-UHFFFAOYSA-N 0.000 description 1
- WNVLQYNNHQWMHM-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone;hydrochloride Chemical compound Cl.C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 WNVLQYNNHQWMHM-UHFFFAOYSA-N 0.000 description 1
- MJCZCHGQXQZPRH-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(4-propan-2-ylpiperazin-1-yl)methanone;hydrochloride Chemical compound Cl.C1CN(C(C)C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 MJCZCHGQXQZPRH-UHFFFAOYSA-N 0.000 description 1
- UBIUTRJXLUTLDV-UHFFFAOYSA-N [4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-[4-(2-methoxyethyl)piperazin-1-yl]methanone;hydrochloride Chemical compound Cl.C1CN(CCOC)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 UBIUTRJXLUTLDV-UHFFFAOYSA-N 0.000 description 1
- MOOUYDFWJLJXCM-UHFFFAOYSA-N [4-[[5-fluoro-4-[3-methyl-2-(trifluoromethyl)imidazol-4-yl]pyrimidin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone;hydrochloride Chemical compound Cl.C1CN(C)CCN1C(=O)C(C=C1)=CC=C1NC1=NC=C(F)C(C=2N(C(=NC=2)C(F)(F)F)C)=N1 MOOUYDFWJLJXCM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 230000007000 age related cognitive decline Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000008335 axon cargo transport Effects 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- QUBNJIAOXXXPIN-UHFFFAOYSA-N azetidin-1-yl-[2-chloro-4-[[4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-yl]amino]phenyl]methanone Chemical compound CN1C(C)=NC=C1C1=NC(NC=2C=C(Cl)C(C(=O)N3CCC3)=CC=2)=NC=C1F QUBNJIAOXXXPIN-UHFFFAOYSA-N 0.000 description 1
- ZDCPXKIZEBPVMR-UHFFFAOYSA-N azetidin-1-yl-[4-[[4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-yl]amino]-2-(trifluoromethoxy)phenyl]methanone Chemical compound CN1C(C)=NC=C1C1=NC(NC=2C=C(OC(F)(F)F)C(C(=O)N3CCC3)=CC=2)=NC=C1F ZDCPXKIZEBPVMR-UHFFFAOYSA-N 0.000 description 1
- FTHCWKRERBWFLI-UHFFFAOYSA-N azetidin-1-yl-[4-[[4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-yl]amino]-2-methylphenyl]methanone Chemical compound CN1C(C)=NC=C1C1=NC(NC=2C=C(C)C(C(=O)N3CCC3)=CC=2)=NC=C1F FTHCWKRERBWFLI-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- SNIABFMMCKVXSY-UHFFFAOYSA-N benzoylazanium;chloride Chemical compound Cl.NC(=O)C1=CC=CC=C1 SNIABFMMCKVXSY-UHFFFAOYSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- CWBHKBKGKCDGDM-UHFFFAOYSA-N bis[(2,2,2-trifluoroacetyl)oxy]boranyl 2,2,2-trifluoroacetate Chemical compound FC(F)(F)C(=O)OB(OC(=O)C(F)(F)F)OC(=O)C(F)(F)F CWBHKBKGKCDGDM-UHFFFAOYSA-N 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- YCBJOQUNPLTBGG-UHFFFAOYSA-N ethyl 4-iodobenzoate Chemical compound CCOC(=O)C1=CC=C(I)C=C1 YCBJOQUNPLTBGG-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000000806 fluorine-19 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000009579 hair morphogenesis Effects 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- VZDNXXPBYLGWOS-UHFFFAOYSA-N methyl 3-aminobenzoate Chemical compound COC(=O)C1=CC=CC(N)=C1 VZDNXXPBYLGWOS-UHFFFAOYSA-N 0.000 description 1
- GXKNRVYAHVTJIV-UHFFFAOYSA-N methyl 4-[[4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-yl]amino]-2-(trifluoromethoxy)benzoate Chemical compound C1=C(OC(F)(F)F)C(C(=O)OC)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C)=N1 GXKNRVYAHVTJIV-UHFFFAOYSA-N 0.000 description 1
- 125000006178 methyl benzyl group Chemical group 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- GCWULTFPRZGPTR-UHFFFAOYSA-N n,5-dimethyl-1,2-oxazol-4-amine Chemical compound CNC=1C=NOC=1C GCWULTFPRZGPTR-UHFFFAOYSA-N 0.000 description 1
- PNJPYAABUAYTTP-UHFFFAOYSA-N n,n-diethyl-4-[[4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N(CC)CC)=CC=C1NC1=NC=CC(C=2N(C(C)=NC=2)C2CCOCC2)=N1 PNJPYAABUAYTTP-UHFFFAOYSA-N 0.000 description 1
- TZGRCZZOGMTHCC-UHFFFAOYSA-N n,n-diethyl-4-[[5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-yl]amino]benzamide;hydrochloride Chemical compound Cl.C1=CC(C(=O)N(CC)CC)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 TZGRCZZOGMTHCC-UHFFFAOYSA-N 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- WYAYYHGIYLDBPQ-UHFFFAOYSA-N n-(3,5-dichlorophenyl)-4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-amine Chemical compound CN1C(C)=NC=C1C1=NC(NC=2C=C(Cl)C=C(Cl)C=2)=NC=C1F WYAYYHGIYLDBPQ-UHFFFAOYSA-N 0.000 description 1
- COJHDBHDKGBAEG-UHFFFAOYSA-N n-(3-chloro-4-methylsulfonylphenyl)-4-(2,3-dimethylimidazol-4-yl)-5-fluoropyrimidin-2-amine Chemical compound CN1C(C)=NC=C1C1=NC(NC=2C=C(Cl)C(=CC=2)S(C)(=O)=O)=NC=C1F COJHDBHDKGBAEG-UHFFFAOYSA-N 0.000 description 1
- FDAWKHKYKBSRPL-UHFFFAOYSA-N n-(4-ethylsulfonylphenyl)-5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 FDAWKHKYKBSRPL-UHFFFAOYSA-N 0.000 description 1
- SQEGJYNDOTYXRX-UHFFFAOYSA-N n-(5-methyl-1,2-oxazol-4-yl)-n-(oxan-4-yl)formamide Chemical compound O1N=CC(N(C=O)C2CCOCC2)=C1C SQEGJYNDOTYXRX-UHFFFAOYSA-N 0.000 description 1
- XRRKFJUDMHRFHP-UHFFFAOYSA-N n-[3-chloro-4-(4-methylpiperazin-1-yl)sulfonylphenyl]-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1CN(C)CCN1S(=O)(=O)C(C(=C1)Cl)=CC=C1NC1=NC=CC(C=2N(C(C)=NC=2)C2CCOCC2)=N1 XRRKFJUDMHRFHP-UHFFFAOYSA-N 0.000 description 1
- QRKLMCCNSYLNSW-UHFFFAOYSA-N n-[4-(azetidin-1-ylsulfonyl)phenyl]-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1COCCC1N1C(C)=NC=C1C(N=1)=CC=NC=1NC(C=C1)=CC=C1S(=O)(=O)N1CCC1 QRKLMCCNSYLNSW-UHFFFAOYSA-N 0.000 description 1
- VMMFFIVOFLAJKC-UHFFFAOYSA-N n-[4-(azetidin-1-ylsulfonyl)phenyl]-5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1COCCC1N1C(C)=NC=C1C(C(=CN=1)F)=NC=1NC(C=C1)=CC=C1S(=O)(=O)N1CCC1 VMMFFIVOFLAJKC-UHFFFAOYSA-N 0.000 description 1
- ZRLJFHYCTGWKJS-UHFFFAOYSA-N n-[4-[(dimethylamino)methyl]phenyl]-5-fluoro-4-[2-methyl-3-(oxan-4-yl)imidazol-4-yl]pyrimidin-2-amine Chemical compound C1=CC(CN(C)C)=CC=C1NC1=NC=C(F)C(C=2N(C(C)=NC=2)C2CCOCC2)=N1 ZRLJFHYCTGWKJS-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 230000001123 neurodevelopmental effect Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 210000002511 neuropil thread Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- HVFSJXUIRWUHRG-UHFFFAOYSA-N oic acid Natural products C1CC2C3CC=C4CC(OC5C(C(O)C(O)C(CO)O5)O)CC(O)C4(C)C3CCC2(C)C1C(C)C(O)CC(C)=C(C)C(=O)OC1OC(COC(C)=O)C(O)C(O)C1OC(C(C1O)O)OC(COC(C)=O)C1OC1OC(CO)C(O)C(O)C1O HVFSJXUIRWUHRG-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- VUNPWIPIOOMCPT-UHFFFAOYSA-N piperidin-3-ylmethanol Chemical compound OCC1CCCNC1 VUNPWIPIOOMCPT-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000004928 piperidonyl group Chemical group 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 description 1
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical class [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- SHNUBALDGXWUJI-UHFFFAOYSA-N pyridin-2-ylmethanol Chemical compound OCC1=CC=CC=N1 SHNUBALDGXWUJI-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- LZOZLBFZGFLFBV-UHFFFAOYSA-N sulfene Chemical group C=S(=O)=O LZOZLBFZGFLFBV-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-FIBGUPNXSA-N trideuteriomethanol Chemical compound [2H]C([2H])([2H])O OKKJLVBELUTLKV-FIBGUPNXSA-N 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0502174 | 2005-10-03 | ||
| NZ566804A NZ566804A (en) | 2005-10-03 | 2006-10-02 | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ591316A true NZ591316A (en) | 2012-06-29 |
Family
ID=37906403
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ566804A NZ566804A (en) | 2005-10-03 | 2006-10-02 | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease |
| NZ591316A NZ591316A (en) | 2005-10-03 | 2006-10-02 | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's disease |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ566804A NZ566804A (en) | 2005-10-03 | 2006-10-02 | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20090105252A1 (enExample) |
| EP (1) | EP1945628A4 (enExample) |
| JP (1) | JP2009513575A (enExample) |
| KR (1) | KR20080059423A (enExample) |
| CN (1) | CN101326179A (enExample) |
| AR (1) | AR058073A1 (enExample) |
| AU (2) | AU2006297890B2 (enExample) |
| BR (1) | BRPI0616658A2 (enExample) |
| CA (1) | CA2624875A1 (enExample) |
| EC (1) | ECSP088405A (enExample) |
| IL (1) | IL190150A0 (enExample) |
| NO (1) | NO20082067L (enExample) |
| NZ (2) | NZ566804A (enExample) |
| RU (2) | RU2433128C2 (enExample) |
| SG (1) | SG166125A1 (enExample) |
| TW (1) | TW200800957A (enExample) |
| UA (1) | UA92181C2 (enExample) |
| UY (1) | UY29827A1 (enExample) |
| WO (1) | WO2007040440A1 (enExample) |
| ZA (1) | ZA200802897B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003208479A1 (en) | 2002-03-09 | 2003-09-22 | Astrazeneca Ab | 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| TW200811169A (en) * | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
| TW200815417A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds II |
| WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
| WO2009017454A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960 |
| WO2009017455A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor |
| NZ590283A (en) * | 2008-07-14 | 2012-11-30 | Gilead Sciences Inc | Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors |
| NZ590320A (en) | 2008-07-14 | 2012-12-21 | Gilead Sciences Inc | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| EP2303841A1 (en) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
| MX2011001090A (es) | 2008-07-28 | 2011-03-15 | Gilead Sciences Inc | Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno. |
| WO2010033977A2 (en) | 2008-09-22 | 2010-03-25 | Cayman Chemical Company | Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| EP2419425A4 (en) * | 2009-04-15 | 2012-08-29 | Astrazeneca Ab | IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS, SUCH AS ALZHEIMER'S DISEASE |
| GB0908772D0 (en) * | 2009-05-21 | 2009-07-01 | Astrazeneca Ab | New salts 756 |
| US8283357B2 (en) | 2009-06-08 | 2012-10-09 | Gilead Sciences, Inc. | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds |
| KR20120031170A (ko) | 2009-06-08 | 2012-03-30 | 길리애드 사이언시즈, 인코포레이티드 | 알카노일아미노 벤즈아미드 아닐린 hdac 저해제 화합물 |
| WO2012050517A1 (en) * | 2010-10-14 | 2012-04-19 | Astrazeneca Ab | Imidazole substituted pyrimidine having a high gsk3 inhibiting potency as well as pan-kinase selectivity |
| CZ305457B6 (cs) | 2011-02-28 | 2015-09-30 | Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. | Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití |
| EP3741375A1 (en) | 2014-07-17 | 2020-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating neuromuscular junction-related diseases |
| WO2016207366A1 (en) | 2015-06-26 | 2016-12-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of viral infections |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| KR102342803B1 (ko) * | 2020-03-23 | 2021-12-24 | 환인제약 주식회사 | 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물 |
| CA3172750A1 (en) * | 2020-03-23 | 2021-09-30 | Ge Hyeong Lee | Novel pyrimidine derivative, and composition for preventing or treating neurodegenerative diseases and cancer, comprising same |
| TW202227401A (zh) * | 2020-10-23 | 2022-07-16 | 大陸商重慶兩江藥物研發中心有限公司 | 用於持續釋放治療劑的前藥及其用途 |
| JP7522315B2 (ja) * | 2020-10-29 | 2024-07-24 | 蘇州亜宝薬物研発有限公司 | 置換ジアリールアミン化合物及びその医薬組成物、製造方法と用途 |
| US20240239774A1 (en) * | 2021-04-28 | 2024-07-18 | Cornell University | Soluble adenylyl cyclase (sac) inhibitors and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3530710A1 (de) | 1985-08-28 | 1987-03-05 | Hoechst Ag | Verfahren zur herstellung von halogenphenyl-oxethyl-sulfiden und deren oxidationsprodukten |
| GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| ES2316546T3 (es) * | 2001-02-20 | 2009-04-16 | Astrazeneca Ab | 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3. |
| SE0100569D0 (sv) * | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | New compounds |
| SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| EA007298B1 (ru) * | 2001-11-01 | 2006-08-25 | Янссен Фармацевтика Н.В. | Гетероариламины в качестве ингибиторов гликогенсинтаза-киназы 3-бета (ингибиторов gsk3) |
| AU2003208479A1 (en) * | 2002-03-09 | 2003-09-22 | Astrazeneca Ab | 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity |
| GB0205693D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| US7361665B2 (en) * | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
| WO2004072063A1 (en) * | 2003-02-07 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
| WO2004083203A1 (en) * | 2003-03-13 | 2004-09-30 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
| GB0311276D0 (en) * | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| JP2007500178A (ja) * | 2003-07-30 | 2007-01-11 | サイクラセル・リミテッド | プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体 |
| TW200528101A (en) * | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| US7132651B2 (en) | 2004-04-23 | 2006-11-07 | Framatome Anp, Inc. | In-situ BWR and PWR CRUD flake analysis method and tool |
| BRPI0614502A2 (pt) * | 2005-07-30 | 2011-03-29 | Astrazeneca Ab | Composto, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto |
| TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
| EP2419425A4 (en) * | 2009-04-15 | 2012-08-29 | Astrazeneca Ab | IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS, SUCH AS ALZHEIMER'S DISEASE |
-
2006
- 2006-09-29 AR ARP060104310A patent/AR058073A1/es not_active Application Discontinuation
- 2006-09-29 UY UY29827A patent/UY29827A1/es not_active Application Discontinuation
- 2006-10-02 KR KR1020087010755A patent/KR20080059423A/ko not_active Ceased
- 2006-10-02 JP JP2008534486A patent/JP2009513575A/ja active Pending
- 2006-10-02 AU AU2006297890A patent/AU2006297890B2/en not_active Ceased
- 2006-10-02 UA UAA200802783A patent/UA92181C2/ru unknown
- 2006-10-02 CN CNA2006800454648A patent/CN101326179A/zh active Pending
- 2006-10-02 EP EP06799716A patent/EP1945628A4/en not_active Withdrawn
- 2006-10-02 RU RU2008110910/04A patent/RU2433128C2/ru not_active IP Right Cessation
- 2006-10-02 NZ NZ566804A patent/NZ566804A/en not_active IP Right Cessation
- 2006-10-02 US US12/089,008 patent/US20090105252A1/en not_active Abandoned
- 2006-10-02 SG SG201007265-0A patent/SG166125A1/en unknown
- 2006-10-02 WO PCT/SE2006/001116 patent/WO2007040440A1/en not_active Ceased
- 2006-10-02 NZ NZ591316A patent/NZ591316A/en not_active IP Right Cessation
- 2006-10-02 CA CA002624875A patent/CA2624875A1/en not_active Abandoned
- 2006-10-02 BR BRPI0616658-0A patent/BRPI0616658A2/pt not_active IP Right Cessation
- 2006-10-03 TW TW095136796A patent/TW200800957A/zh unknown
-
2008
- 2008-03-13 IL IL190150A patent/IL190150A0/en not_active IP Right Cessation
- 2008-04-02 ZA ZA200802897A patent/ZA200802897B/xx unknown
- 2008-04-28 EC EC2008008405A patent/ECSP088405A/es unknown
- 2008-04-30 NO NO20082067A patent/NO20082067L/no not_active Application Discontinuation
-
2011
- 2011-03-03 AU AU2011200948A patent/AU2011200948A1/en not_active Abandoned
- 2011-04-20 RU RU2011115406/04A patent/RU2011115406A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200800957A (en) | 2008-01-01 |
| EP1945628A1 (en) | 2008-07-23 |
| EP1945628A4 (en) | 2010-06-02 |
| BRPI0616658A2 (pt) | 2011-06-28 |
| SG166125A1 (en) | 2010-11-29 |
| ZA200802897B (en) | 2008-12-31 |
| IL190150A0 (en) | 2008-08-07 |
| KR20080059423A (ko) | 2008-06-27 |
| UY29827A1 (es) | 2007-05-31 |
| NZ566804A (en) | 2011-03-31 |
| AU2006297890B2 (en) | 2011-04-28 |
| WO2007040440A1 (en) | 2007-04-12 |
| AU2011200948A1 (en) | 2011-03-24 |
| AR058073A1 (es) | 2008-01-23 |
| AU2006297890A1 (en) | 2007-04-12 |
| CN101326179A (zh) | 2008-12-17 |
| NO20082067L (no) | 2008-07-02 |
| RU2433128C2 (ru) | 2011-11-10 |
| RU2008110910A (ru) | 2009-11-10 |
| JP2009513575A (ja) | 2009-04-02 |
| UA92181C2 (ru) | 2010-10-11 |
| ECSP088405A (es) | 2008-05-30 |
| US20090105252A1 (en) | 2009-04-23 |
| CA2624875A1 (en) | 2007-04-12 |
| RU2011115406A (ru) | 2012-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006297890B2 (en) | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's disease | |
| EP1492785B9 (en) | 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors | |
| AU2007265732A1 (en) | Imidazol-pyrimidine derivatives for treatment of diseases related to glycogen synthase kinase (GSK3) | |
| US20080188502A1 (en) | New Compounds I | |
| US7683067B2 (en) | 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3) | |
| US20110028489A1 (en) | Pyrimidine Derivatives and Their Use for Treating Bone-Related Disorders | |
| AU2003287137B2 (en) | Novel compounds having selective inhibiting effect at GSK3 | |
| HK1126482A (en) | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease | |
| HK1080854B (en) | Compounds having selective inhibiting efect at gsk3 | |
| HK1071360B (en) | 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors | |
| HK1120512A (en) | 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |